biote Corp. (BTMD)
Valuation Overview•Is biote Corp. Overvalued or Undervalued?
Trading at a relative discount to industry peers, suggesting a specific risk premium is applied.
Moderate quality score of 63/100, reflecting stable operating margins and manageable leverage.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Solid fundamental quality, though solvency presents a headwind.
Wall Street is highly bullish, projecting significant upside. This outlook is strongly supported by highly attractive capital returns, driven by a balanced mix of reliable dividends and share buybacks.
BTMD demonstrates strong business quality with robust profitability and healthy margins (highlighted by a massive 1129.3% ROIC). This is paired with a moderately leveraged but stable balance sheet.
The company demonstrates solid revenue growth (5.2% 3Y CAGR) paired with highly explosive earnings growth (66.6% EPS 3Y CAGR). The company maintains healthy operational efficiency with a 15.4% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $44.9M | -2.5% | +5.2% | +10.5% | — | |
| EBITDA | $3.2M | — | — | — | — | |
| Net Income | $2.3M | +756.7% | — | — | — | |
| EPS (Diluted) | $0.06 | +703.5% | +66.6% | -28.1% | — | |
| Free Cash Flow | $3.5M | -22.2% | — | +3.8% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 70.1% | 70.3% | 68.5% | 66.4% |
| Operating Margin | 15.4% | 16.7% | 7.6% | 12.4% |
| Net Margin | 8.3% | 5.8% | 8.1% | 12.1% |
| FCF Margin | 15.2% | 16.1% | 12.6% | 15.2% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.09 | $0.06 | -33.3% | ||
| Q1'26 | $0.05 | $0.06 | +20.0% | ||
| Q4'25 | $0.05 | $0.22 | +340.0% | ||
| Q3'25 | $0.06 | $0.10 | +66.7% | ||
| Q2'25 | $0.06 | $0.08 | +33.3% | ||
| Q1'25 | $0.09 | $0.10 | +11.1% | ||
| Q4'24 | $0.09 | $0.33 | +266.7% | ||
| Q3'24 | $0.09 | $0.14 | +55.6% |
Total return is -43.4% (1Y), lagging the benchmark by -68.3%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -8.5% | -17.8% | — |
| 1Y | -43.4% | -68.3% | — |
| 3YCAGR | -28.1% | -47.5% | — |
| 5YCAGR | -25.6% | -37.8% | — |
| 10YCAGR | -13.9% | -27.5% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about biote Corp. (BTMD) valuation, health, and returns.
Based on peer relative multiples, biote Corp. appears Cheap versus peers compared to industry peers.
biote Corp. has multiple valuation anchors: Peer Relative Fair Value: $12.67 | Wall Street Analyst Target: $3.25 (implying +43.8% upside). A convergence of these signals offers higher conviction.
biote Corp. displays good financial health with a composite quality score of 63/100, supported by a Altman Z-Score of 1.4 (distress zone), Piotroski F-Score of 6/9, Return on Invested Capital (ROIC) of 1129.3%.
biote Corp. pays a 2.1% dividend yield, covered by a 6% payout ratio with 0 years of growth, supplemented by a 3.4% buyback yield.
biote Corp.'s current growth trajectory is Decelerating. The company achieved -2.5% 1Y revenue growth and +703.5% 1Y EPS growth, compared to its 3Y revenue CAGR of +5.2%.
Wall Street consensus is Buy based on 7 analysts, beating EPS expectations in 83% of recent quarters with a -1-quarter streak. The consensus price target represents a +43.8% change from current levels.
Investment risks for biote Corp. include: -71.4% 1-year max drawdown, high beta (1.30x market volatility), elevated distress risk. Volatility risk is characterized by a beta of 1.30x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.